Vera Therapeutics (VERA) Competitors $30.33 +0.13 (+0.43%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$30.34 +0.01 (+0.03%) As of 10/21/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. ABVX, RNA, CYTK, MRUS, RYTM, CRSP, GRFS, NUVL, AXSM, and LEGNShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Merus (MRUS), Rhythm Pharmaceuticals (RYTM), CRISPR Therapeutics (CRSP), Grifols (GRFS), Nuvalent (NUVL), Axsome Therapeutics (AXSM), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Its Competitors Abivax Avidity Biosciences Cytokinetics Merus Rhythm Pharmaceuticals CRISPR Therapeutics Grifols Nuvalent Axsome Therapeutics Legend Biotech Abivax (NASDAQ:ABVX) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership. Is ABVX or VERA more profitable? Abivax's return on equity of 0.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AbivaxN/A N/A N/A Vera Therapeutics N/A -46.70%-39.46% Do institutionals & insiders have more ownership in ABVX or VERA? 47.9% of Abivax shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 16.3% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more risk & volatility, ABVX or VERA? Abivax has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Does the media prefer ABVX or VERA? In the previous week, Vera Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 8 mentions for Vera Therapeutics and 4 mentions for Abivax. Vera Therapeutics' average media sentiment score of 0.69 beat Abivax's score of 0.47 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer ABVX or VERA? Abivax presently has a consensus price target of $114.25, indicating a potential upside of 24.63%. Vera Therapeutics has a consensus price target of $61.50, indicating a potential upside of 102.77%. Given Vera Therapeutics' higher probable upside, analysts clearly believe Vera Therapeutics is more favorable than Abivax.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abivax 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.91Vera Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Which has higher earnings & valuation, ABVX or VERA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbivaxN/AN/A-$190.71MN/AN/AVera TherapeuticsN/AN/A-$152.15M-$3.58-8.47 SummaryVera Therapeutics beats Abivax on 7 of the 12 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.93B$3.47B$6.21B$10.68BDividend YieldN/A2.27%5.72%4.88%P/E Ratio-8.4723.0629.1427.23Price / SalesN/A497.37587.91132.66Price / CashN/A47.5937.5161.65Price / Book3.3410.6612.526.59Net Income-$152.15M-$52.56M$3.32B$276.14M7 Day Performance-2.16%2.64%0.77%-0.72%1 Month Performance16.16%13.86%7.29%2.47%1 Year Performance-25.50%14.85%64.58%33.90% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics2.8909 of 5 stars$30.33+0.4%$61.50+102.8%-25.8%$1.93BN/A-8.4740ABVXAbivax3.5041 of 5 stars$95.63+2.0%$114.25+19.5%+773.0%$7.30BN/A0.0061Short Interest ↓RNAAvidity Biosciences2.6335 of 5 stars$48.96-1.6%$68.32+39.5%+5.0%$7.26B$10.90M-13.75190CYTKCytokinetics3.8703 of 5 stars$59.59-0.7%$76.64+28.6%+7.4%$7.18B$18.47M-11.68250Trending NewsAnalyst ForecastInsider TradeMRUSMerus1.4852 of 5 stars$94.85+0.5%$93.12-1.8%+83.3%$7.14B$36.13M-17.2537Short Interest ↓RYTMRhythm Pharmaceuticals3.0379 of 5 stars$100.770.0%$106.64+5.8%+113.5%$6.70B$130.13M-33.48140Insider TradeCRSPCRISPR Therapeutics1.957 of 5 stars$68.29-6.5%$71.71+5.0%+49.1%$6.65B$37.31M-12.58460Insider TradeGap UpGRFSGrifols4.0519 of 5 stars$9.45+1.4%$10.30+9.0%+9.0%$6.41B$7.81B8.0823,822Positive NewsNUVLNuvalent2.6314 of 5 stars$89.75+1.9%$118.89+32.5%-3.9%$6.35BN/A-18.3240Analyst RevisionAXSMAxsome Therapeutics4.7844 of 5 stars$121.15-0.5%$177.93+46.9%+43.6%$6.07B$385.69M-23.90380Positive NewsAnalyst ForecastLEGNLegend Biotech2.9421 of 5 stars$32.85+3.6%$69.25+110.8%-24.4%$5.85B$627.24M-37.332,609High Trading Volume Related Companies and Tools Related Companies Abivax Competitors Avidity Biosciences Competitors Cytokinetics Competitors Merus Competitors Rhythm Pharmaceuticals Competitors CRISPR Therapeutics Competitors Grifols Competitors Nuvalent Competitors Axsome Therapeutics Competitors Legend Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you can be at your computer between 9 a.m. and 10:45 a.m. on most weekdays, I’ll show you a simple trading ...Base Camp Trading | SponsoredThe Republican party is falling apartSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
